Workspaces
Log in Sign up

Zynlonta Confirmatory Phase 3 Trial Meets PFS Endpoint but Staggering 3-to-1 Death Imbalance Clouds FDA Path

Updated

Sources

Zynlonta Confirmatory Phase 3 Trial Meets PFS Endpoint but Staggering 3-to-1 Death Imbalance Clouds FDA Path

On June 3, 2026, ADC Therapeutics announced topline results from its Phase 3 LOTIS-5 confirmatory trial evaluating Zynlonta (loncastuximab tesirine-lpyl), a CD19-directed antibody-drug conjugate (ADC), in combination with rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). While the trial met its primary endpoint of progression-free survival (PFS), a severe safety signal was revealed: 27 patient deaths occurred in the Zynlonta-treatment arm compared to just 9 deaths in the control arm1 (a stark 3-to-1 death imbalance), and no overall survival (OS) benefit was demonstrated.

This safety setback caused ADC Therapeutics' stock to crash 66% over the span of a month, prompting a major strategic reorganization.

On June 24, 2026, ADC Therapeutics announced a 17% global workforce reduction (affecting approximately 30 to 32 roles) in an effort to save $10 million in annualized costs and extend its cash runway into 2028. Despite the layoffs and intense analyst skepticism regarding second-line utilization of Zynlonta, the company is pushing forward with its regulatory strategy.

CEO Ameet Mallik confirmed that ADC Therapeutics remains engaged with the FDA. The company is preparing for a key pre-supplemental Biologics License Application (sBLA) meeting with the FDA in August 2026 and still plans to submit its sBLA for expanded approval in Q4 2026, arguing that the majority of deaths occurred in patients aged 75 and older and that the overall benefit-risk profile remains favorable.

  1. An instance of Clinical breakthroughs cannot secure a market path if patients cannot tolerate the safety trade-offs. — The drug's efficacy breakthrough in PFS is severely undermined by a fatal safety signal that threatens its regulatory and commercial trajectory. ↩︎

Part of

This finding is an example of a pattern recurring across your work:

Revision history

  • Update with ADC Therapeutics' June 24, 2026 strategic reorganization and 17% global workforce reduction following the LOTIS-5 safety concerns, while confirming plans for the August pre-sBLA meeting and Q4 2026 sBLA submission.
    · by the agent
  • Update note with detailed Phase 3 LOTIS-5 safety and efficacy data points, and the planned August pre-sBLA meeting and Q4 sBLA submission.
    · by the agent
  • Update note with detailed Phase 3 LOTIS-5 safety and efficacy data points, and the planned August pre-sBLA meeting and Q4 sBLA submission.
    · by the agent
  • Update note with detailed Phase 3 LOTIS-5 safety and efficacy data points, and the planned August pre-sBLA meeting and Q4 sBLA submission.
    · by the agent
  • Update note with detailed Phase 3 LOTIS-5 safety and efficacy data points, and the planned August pre-sBLA meeting and Q4 sBLA submission.
    · by the agent
  • Update note with detailed Phase 3 LOTIS-5 safety and efficacy data points, and the planned August pre-sBLA meeting and Q4 sBLA submission.
    · by the agent
  • Update note with detailed Phase 3 LOTIS-5 safety and efficacy data points, and the planned August pre-sBLA meeting and Q4 sBLA submission.
    · by the agent
  • Update note with detailed Phase 3 LOTIS-5 safety and efficacy data points, and the planned August pre-sBLA meeting and Q4 sBLA submission.
    · by the agent
  • Update note with detailed Phase 3 LOTIS-5 safety and efficacy data points, and the planned August pre-sBLA meeting and Q4 sBLA submission.
    · by the agent
  • Update note with detailed Phase 3 LOTIS-5 safety and efficacy data points, and the planned August pre-sBLA meeting and Q4 sBLA submission.
    · by the agent
  • Update note with detailed Phase 3 LOTIS-5 safety and efficacy data points, and the planned August pre-sBLA meeting and Q4 sBLA submission.
    · by the agent
  • Update note with detailed Phase 3 LOTIS-5 safety and efficacy data points, and the planned August pre-sBLA meeting and Q4 sBLA submission.
    · by the agent
  • Update note with detailed Phase 3 LOTIS-5 safety and efficacy data points, and the planned August pre-sBLA meeting and Q4 sBLA submission.
    · by the agent
  • Update note with detailed Phase 3 LOTIS-5 safety and efficacy data points, and the planned August pre-sBLA meeting and Q4 sBLA submission.
    · by the agent
  • Update note with detailed Phase 3 LOTIS-5 safety and efficacy data points, and the planned August pre-sBLA meeting and Q4 sBLA submission.
    · by the agent
  • Update the Zynlonta LOTIS-5 confirmatory trial note with the detailed topline Phase 3 results, highlighting the positive PFS efficacy but focusing heavily on the severe safety concerns, including the 13.2% (27 patients) fatal TEAE rate and nearly 3-to-1 death imbalance vs control.
    · by the agent
  • Update the Zynlonta LOTIS-5 confirmatory trial note with the detailed topline Phase 3 results, highlighting the positive PFS efficacy but focusing heavily on the severe safety concerns, including the 13.2% (27 patients) fatal TEAE rate and nearly 3-to-1 death imbalance vs control.
    · by the agent
  • Update the Zynlonta LOTIS-5 confirmatory trial note with the detailed topline Phase 3 results, highlighting the positive PFS efficacy but focusing heavily on the severe safety concerns, including the 13.2% (27 patients) fatal TEAE rate and nearly 3-to-1 death imbalance vs control.
    · by the agent
  • Write a new finding for LOTIS-5 trial results showing PFS win but 3x death rate, causing the stock to drop over 50%.
    · by the agent